AngioDynamics (ANGO) is back on investors’ radar after its Med Tech platforms helped deliver stronger quarterly results, prompting management to raise full year revenue and profitability guidance while outlining an upcoming CEO transition.

Even with the raised guidance and progress in Med Tech platforms, AngioDynamics’ 7 day share price return of 21.73% and 30 day share price return of 23.63% suggest recent momentum has faded, aligning with a 1 year total shareholder return of 22.33% and a 5 year total shareholder return of 46.00%.

If this update has you rethinking your exposure to medical devices, it could be a good moment to scan other opportunities across healthcare stocks for fresh ideas in the sector.

After a strong run in Med Tech and a sharp pullback in the share price, AngioDynamics now trades at US$10.05 with a value score of 2 and a sizeable gap to analyst targets. Is this a reset entry point, or is the market already baking in the company’s next leg of growth?

Most Popular Narrative: 44.9% Undervalued

With a fair value estimate of US$18.25 against the last close at US$10.05, the most followed narrative points to a wide valuation gap built on specific growth and margin assumptions.

Ongoing clinical validation, expanding regulatory approvals, and upcoming reimbursement enhancements (notably the new CPT codes for NanoKnife prostate and pancreatic cancer procedures effective 2026 and 2027) are expected to accelerate adoption of higher-margin products, positively affecting both revenue and net margins over the next several years.

Curious what kind of revenue ramp, margin shift, and future earnings multiple are being used to justify that valuation gap, and how ambitious those assumptions really are?

Result: Fair Value of $18.25 (UNDERVALUED)

However, analysts’ narrative could be challenged if tariff pressures squeeze margins further, or if reimbursement and regulatory delays slow uptake in core platforms such as NanoKnife and AlphaVac.

Build Your Own AngioDynamics Narrative

If you look at the numbers and reach a different conclusion, or just prefer to test your own assumptions, you can build a custom thesis in a few minutes, starting with Do it your way

A good starting point is our analysis highlighting 1 key reward investors are optimistic about regarding AngioDynamics.

Ready to hunt for your next idea?

If AngioDynamics has sharpened your thinking, do not stop here. Use the screener to quickly surface other stocks that might fit what you are looking for.

• Target higher income potential by scanning these 11 dividend stocks with yields > 3% that could complement a more growth focused portfolio.
• Spot early growth stories by checking out these 3544 penny stocks with strong financials that pair smaller size with stronger financial foundations.
• Ride long term tech trends by reviewing these 28 AI penny stocks that sit at the crossroads of software, data and automation.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.